Carl D. Regillo, MD: Key Factors of Faricimab In Neovascular AMD Treatment
Dr. Regillo discusses the efficacy and durability of faricimab for wet AMD treatment in TENAYA and LUCERNE, showing noninferiority to aflibercept.
Rishi P. SIngh, MD: Advances and Challenges in Neovascular AMD Treatment
Dr. Singh discusses the aging population in ophthalmology care, advances including port delivery systems, and the potential rapid uptake of faricimab in treatment.
US Patient Access to Ophthalmology Clinical Trial Sites Differs by Regions
A geographical study shows patients in areas with lower income, education, and higher rates of ophthalmic disease may be a greater distance from a trial site.
Rishi P. SIngh, MD: Durability of Faricimab in Neovascular AMD Treatment
Dr. Singh discusses results from TENAYA and LUCERNE on faricimab compared to afilbercept in patients with nAMD.
Ranibizumab Biosimilar FYB201 Provides Similar Efficacy, Safety in Phase 3 Trial
The COLUMBUS-AMD trial suggests the investigative biosimilar could benefit patients newly diagnosed with nAMD.
New Model Could Predict Cost of PDR Prevention with Aflibercept
A cost-based assessment of Protocol W and PANORAMA clinical data suggests diabetic retinopathy may be less costly to prevent than macular edema.
Paul Sternberg, MD: Perspectives on Step Therapy in Wet AMD Treatment
Dr. Sternberg discusses step therapy in wetAMD treatment and his opinions in favor of its use.
Bevacizumab Formulation Significantly Improves wAMD Vision Versus Ranibizumab in NORSE 2
Bevacizumab-vikg was associated with statistically significant improvements in patient BCVA scores over a period of 12 months, according to phase 3 findings.
Treat-and-Extend for Anti-VEGF May Provide More Optimal Dosing and Fewer Clinic Visits
A meta-analysis comparison of dosing regimens for patients with nAMD show little difference in efficacy, but differences in patient involvement in care.
Vorolanib via Durasert Provides Safe Treatment of Wet AMD Through 12 Months
A phase 1 trial of the investigative drug suggests its promise in a novel strategy of managing patients with retinal fluid.
David R. Lally, MD: Analyzing Nascent GA, Intermediate AMD Progression from GATHER1
Dr. Lally discusses the effect of avacincaptad pegol treatment on the progression of geographic atrophy and intermediate age-related macular degeneration.
Gene Therapy ADVM-022 Provides Mixed Efficacy, Safety in Treating DME
Findings from the phase 2 INFINITY suggest a more dose-dependent influence on safety outcomes in patients receiving sustained benefit for diabetic macular edema.
Optogenetics Product Provides Safe Treatment Opportunity for Retinitis Pigmentosa Reversal
An update from the PIONEER trial shows the combination gene therapy and medical device strategy is safe and tolerable, while providing cases of improved light perception.
Julia A Haller, MD: Facing Challenges and Finding Solutions in Retina
Dr. Haller discusses issues in diversity and inclusion in retina, but provides avenues for solutions and what needs to come next.
Dosing Variability Risk Could Be High With Aflibercept PFS
An AAO 2021 presentation highlighted the industrial design differences that could result in treatment overdoses with pre-filled syringes of aflibercept.
COVID-19 Lockdowns Drove Fewer Anti-VEGF Injections, Worse Vision in Ophthalmic Patients
Early 2020 response to the pandemic was linked to many patients being lost to follow-up, and countries reported worse overall visual acuity among their patients.
Reduced Retinal Fluid Linked to Better nAMD Visual Improvements
New HAWK and HARRIER findings show patients with fluid-free visits reported greater benefit in BVCA while receiving anti-VEGF.
Thoughts on AAO 2020: Uveitis Subspecialty Day
A uveitis specialist breaks down what occurs during the uveitis-dedicated event and comments on its importance.
Raymond Douglas, MD, PhD: The Shift to Telemedicine in Ophthalmology
Raymond Douglas, MD, PhD discusses how the COVID-19 pandemic has affected his clinical practice and potentially accelerated technological innovation as a whole.
Development of Geographic Atrophy is Similar Across Ranibizumab Dosing Regimens
A post-hoc analysis of the CANTREAT trial finds similar GA frequency, characteristics, and surface area between patients in treat-and-extend and once-monthly regimen cohorts.
New Study Examines Role of Anti-VEGF Injections on Treatment Patterns
There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.
PRN Injections Yields Improvements for Diabetic Retinopathy Patients
In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.
Ranibizumab Associated with Improved Choroid Flow in DME
A recent study presented at AAO 2020 reports that increased choroid vascular flow was noted in both small and large vessels in patients with non-vitrectomized eyes.
Nadia Waheed, MD, MPH: OCT Angiography Predicts DR Progression
A new study from AAO 2020 is the first to show a significant association between peripapillary vessel density loss and progression of diabetic retinopathy.
Ehsan Rahimy, MD: The Importance of Continued Geographic Atrophy Screening
A new IRIS registry analysis reports that many patients with geographic atrophy do not continue follow-up after initial visit or consultation.
Registry Shows Preferences for Invasive Procedures in Pediatric Retinal Detachments
RD surgery and scleral buckle appear to be preferred among ophthalmologists—but are linked to further necessary care in children.
Diabetes Could Influence Glaucoma Patient Microvascular Density
Retinal nerve fiber layer density also appears to be influenced by presentation of both conditions.
Geeta Lalchandani-Lalwani, MD: Screening, Treatment of Diabetic Retinopathy
Geeta Lalchandani-Lalwani, MD discusses the importance of early DR detection as well as findings from her study that suggest a need for more personalized therapies.
Ranibizumab Biosimilar Shows Similar Efficacy through 48 Weeks
A new trial shows treatment-naive patients with nAMD have similar BCVA and safety outcomes with the biosimilar.
Geeta Lalchandani-Lalwani, MD: Diabetic Retinopathy Progression in a Large Dataset
For patients with ETDRS DRSS scores of 47-53, about 40% experienced 2-step DR worsening by year 5.
